Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Thursday, December 3, 2015

Can this treatment become a Clinical Trial for MS?

As the actual cause behind this autoimmune response hasn’t been found, a proper treatment doesn’t exist yet, although there are many clinical trials that focus on reducing the disease’s symptoms, thus improving the daily lives of multiple sclerosis patients. But Ph.D. Chang-Qing Xia’s research on mice with autoimmune encephalomyelitis, made at the University of Florida, promises a lot of hope for future treatments of multiple sclerosis. Although experimental autoimmune encephalomyelitis in mice isn’t identical to multiple sclerosis it is similar enough to take into consideration.
By trying out a method already used to treat autoimmune diseases, researcher Chang-Qing Xia managed to reverse the mice’s disease to early stages. He used a chemical shortly called SMCC or sulfo-SMCC, which is approved by US FDA to help bind the autoantigens of the diseases with spleen cells. This method of binding autoantigens, which are protein fragments of myelin with spleen cells using SMCC is a fast and easy process that is also less toxic to cells when used as a treatment.
M.D. Xia considers that “the most important thing is that these findings are highly translatable to the clinic,” meaning that the next step is finding a way of transforming the successful experiments into a human clinical trial. The researcher’s hypothesis is that the experimental autoimmune encephalomyelitis and multiple sclerosis are similar diseases pathologically and immunologically and by combining human protein fragments of myelin known as autoantigens with white blood cells a transfusion serum could be developed. Hopefully, the same result could be observed in multiple sclerosis, even if the damage cannot be entirely repaired, keeping the disease at an early stage or simply stopping the damaging process could mean a breakthrough for multiple sclerosis treatment.
Read more

MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here

No comments: